The Burrill Report is written for everyone who wants to understand how biotechnology operates as a business. Each month the publication focuses on the health of the industry and the strategies that will be needed to be successful. It provides actionable market intelligence on the latest global developments and trends in the life sciences industry. Available monthly, subscribers also benefit from monthly and quarterly market financial and business statistics on: - Public companies - venture financings - Project Runway – Follow the global life sciences companies filing for and completing their IPOs – and their post market performances - Clinical Trials successes and failures - Patent - M&A and Partnering deals - Periodic country features on Canada, Europe and emerging countries such as China & India. In addition, BR provides in-depth coverage on specific sectors of life sciences including: Personalized Medicine; Diagnostics, Medical Devices and Biogreentech (Ag-Bio and Biofuels/Bioenergy). Through weekly Burrill Indices, the progress and prospects of biotech companies by size, from small through to blue-chip are also tracked. Visit: The Burrill Report to obtain your sample issue (http://www.burrillreport.com/)
Formerly a Wall Street executive from a premier investment bank, author EXP's goal is to help investors discover stocks before the "crowd." The first article published was on "LNG" many years ago; an undiscovered gem. >> BLOG: https://seekingalpha.com/account/authorboard/instablog >>
This is not an easy business. Investing is psychological in nature and can be extremely taxing. Patience is key.
Not all ideas are written about or picked for publication.
EXP works hard to identify and write about current stock opportunities in the market that can produce some huge gains from disconnects in stock prices. These inefficiencies can be taken advantage of if you can properly identify opportunities, and then manage to act on them before the crowd.
EXP resides in the USA and is very thankful to followers worldwide.
You can also follow EXPstocktrader on: Twitter --- @EXPstocktrader Email --- firstname.lastname@example.org > Disclosure: The administrator(s) of the services mentioned here may be long, short, or flat in any position mentioned as disclosed. All statements are made without any representation to its complete accuracy and administrator(s) are not compensated for posting notes by listed companies. Some minimal compensation is paid by SA if the article gets picked for circulation. EXP never takes money from companies to promote or write about a stock. All stock prices shown are approximate. Ratings may change at any time. All posts are for simulation purposes only. All stock trades transacted by you are at your own risk. We trade stocks and do not usually buy and hold indefinitely. Please take any information that you see here and consult your own investment advisor before making any real trades. EXP, EXPstocktrader and Seeking Alpha are Not licensed to give you investment advice based on your own personal suitability and risk tolerances. Please consult with your financial advisor before making any trades that you read about here or anywhere EXPstocktrader publishes information for that matter. Thank you.
Capital Markets consultant and active investor in the emerging life science space. Tenured futures trader. Able to provide access to a pool of investors and traders throughout the US and UK. ProActive Capital, a capital markets advisory firm that makes direct investments and provides advisory services into public and private life science companies. Areas of focus include; capital introduction, shareholder management, communications and investor outreach.